vs

Side-by-side financial comparison of GENESIS ENERGY LP (GEL) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $440.8M, roughly 1.1× GENESIS ENERGY LP). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 4.5%, a 2.3% gap on every dollar of revenue. On growth, GENESIS ENERGY LP posted the faster year-over-year revenue change (10.5% vs -1.7%). Over the past eight quarters, GENESIS ENERGY LP's revenue compounded faster (0.7% CAGR vs -0.1%).

Genesis Energy LP is a U.S.-based midstream energy limited partnership that operates critical infrastructure for crude oil, natural gas, refined petroleum products, and specialty industrial materials. Its core assets include pipelines, storage terminals, marine facilities, and rail logistics hubs, serving refineries, industrial clients, and energy distributors across North America.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

GEL vs MD — Head-to-Head

Bigger by revenue
MD
MD
1.1× larger
MD
$493.8M
$440.8M
GEL
Growing faster (revenue YoY)
GEL
GEL
+12.2% gap
GEL
10.5%
-1.7%
MD
Higher net margin
MD
MD
2.3% more per $
MD
6.8%
4.5%
GEL
Faster 2-yr revenue CAGR
GEL
GEL
Annualised
GEL
0.7%
-0.1%
MD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GEL
GEL
MD
MD
Revenue
$440.8M
$493.8M
Net Profit
$19.9M
$33.7M
Gross Margin
Operating Margin
20.4%
9.9%
Net Margin
4.5%
6.8%
Revenue YoY
10.5%
-1.7%
Net Profit YoY
140.2%
10.5%
EPS (diluted)
$0.04
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GEL
GEL
MD
MD
Q4 25
$440.8M
$493.8M
Q3 25
$414.0M
$492.9M
Q2 25
$377.3M
$468.8M
Q1 25
$398.3M
$458.4M
Q4 24
$398.9M
$502.4M
Q3 24
$397.3M
$511.2M
Q2 24
$430.2M
$504.3M
Q1 24
$434.4M
$495.1M
Net Profit
GEL
GEL
MD
MD
Q4 25
$19.9M
$33.7M
Q3 25
$9.2M
$71.7M
Q2 25
$-406.0K
$39.3M
Q1 25
$-469.1M
$20.7M
Q4 24
$-49.4M
$30.5M
Q3 24
$-17.2M
$19.4M
Q2 24
$-8.7M
$-153.0M
Q1 24
$11.4M
$4.0M
Operating Margin
GEL
GEL
MD
MD
Q4 25
20.4%
9.9%
Q3 25
19.0%
13.8%
Q2 25
17.9%
12.8%
Q1 25
5.5%
7.0%
Q4 24
3.4%
7.8%
Q3 24
12.2%
6.6%
Q2 24
11.6%
-31.3%
Q1 24
13.4%
3.2%
Net Margin
GEL
GEL
MD
MD
Q4 25
4.5%
6.8%
Q3 25
2.2%
14.5%
Q2 25
-0.1%
8.4%
Q1 25
-117.8%
4.5%
Q4 24
-12.4%
6.1%
Q3 24
-4.3%
3.8%
Q2 24
-2.0%
-30.3%
Q1 24
2.6%
0.8%
EPS (diluted)
GEL
GEL
MD
MD
Q4 25
$0.04
$0.40
Q3 25
$-0.05
$0.84
Q2 25
$-0.12
$0.46
Q1 25
$-4.06
$0.24
Q4 24
$-0.58
$0.37
Q3 24
$-0.32
$0.23
Q2 24
$-0.25
$-1.84
Q1 24
$-0.09
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GEL
GEL
MD
MD
Cash + ST InvestmentsLiquidity on hand
$6.4M
$375.2M
Total DebtLower is stronger
$3.0B
$570.5M
Stockholders' EquityBook value
$865.9M
Total Assets
$4.9B
$2.2B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GEL
GEL
MD
MD
Q4 25
$6.4M
$375.2M
Q3 25
$4.9M
$340.1M
Q2 25
$4.5M
$224.7M
Q1 25
$377.4M
$99.0M
Q4 24
$7.4M
$229.9M
Q3 24
$13.0M
$103.8M
Q2 24
$13.7M
$19.4M
Q1 24
$7.0M
$8.0M
Total Debt
GEL
GEL
MD
MD
Q4 25
$3.0B
$570.5M
Q3 25
$3.1B
$577.2M
Q2 25
$3.1B
$583.9M
Q1 25
$3.4B
$590.5M
Q4 24
$3.7B
$597.1M
Q3 24
$4.0B
Q2 24
$3.9B
Q1 24
$3.8B
Stockholders' Equity
GEL
GEL
MD
MD
Q4 25
$865.9M
Q3 25
$890.7M
Q2 25
$833.8M
Q1 25
$789.2M
Q4 24
$764.9M
Q3 24
$732.5M
Q2 24
$706.5M
Q1 24
$856.2M
Total Assets
GEL
GEL
MD
MD
Q4 25
$4.9B
$2.2B
Q3 25
$4.9B
$2.2B
Q2 25
$4.8B
$2.1B
Q1 25
$5.2B
$2.0B
Q4 24
$7.0B
$2.2B
Q3 24
$7.1B
$2.1B
Q2 24
$7.0B
$2.0B
Q1 24
$6.9B
$2.2B
Debt / Equity
GEL
GEL
MD
MD
Q4 25
0.66×
Q3 25
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GEL
GEL
MD
MD
Operating Cash FlowLast quarter
$110.8M
$114.1M
Free Cash FlowOCF − Capex
$87.0M
FCF MarginFCF / Revenue
19.7%
Capex IntensityCapex / Revenue
5.4%
Cash ConversionOCF / Net Profit
5.58×
3.39×
TTM Free Cash FlowTrailing 4 quarters
$65.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GEL
GEL
MD
MD
Q4 25
$110.8M
$114.1M
Q3 25
$70.3M
$137.3M
Q2 25
$47.0M
$137.2M
Q1 25
$24.8M
$-117.5M
Q4 24
$74.0M
$133.0M
Q3 24
$87.3M
$91.8M
Q2 24
$104.7M
$107.0M
Q1 24
$125.9M
$-125.2M
Free Cash Flow
GEL
GEL
MD
MD
Q4 25
$87.0M
Q3 25
$43.3M
Q2 25
$-7.6M
Q1 25
$-56.8M
Q4 24
$-47.1M
Q3 24
$-32.3M
Q2 24
$-67.5M
Q1 24
$-48.3M
FCF Margin
GEL
GEL
MD
MD
Q4 25
19.7%
Q3 25
10.5%
Q2 25
-2.0%
Q1 25
-14.3%
Q4 24
-11.8%
Q3 24
-8.1%
Q2 24
-15.7%
Q1 24
-11.1%
Capex Intensity
GEL
GEL
MD
MD
Q4 25
5.4%
Q3 25
6.5%
Q2 25
14.5%
Q1 25
20.5%
Q4 24
30.3%
Q3 24
30.1%
Q2 24
40.0%
Q1 24
40.1%
Cash Conversion
GEL
GEL
MD
MD
Q4 25
5.58×
3.39×
Q3 25
7.63×
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
Q2 24
Q1 24
11.09×
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GEL
GEL

Onshore Facilities And Transportation Revenue$204.2M46%
Offshore Pipeline Transportation Revenue$154.3M35%
Marine Transportation Revenue$82.2M19%

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons